Alzamend: Novel Lithium Delivery for Alzheimer’s & Mental Health

Alzamend's AL001 aims for better lithium delivery to the brain, potentially revolutionizing Alzheimer's, bipolar disorder, MDD, and PTSD treatment with fewer side effects. Phase 1/2A trials are underway.

Topline information is anticipated in the very first quarter of 2026. Previously, the firm expected topline arise from the initial trial by year-end 2025, with follow-up tests in bipolar disorder, major depressive problem, post-traumatic stress disorder, and Alzheimer’s launching through early 2026.

AL001: Targeted Lithium Delivery

The key objective is to examine how AL001 delivers lithium to the mind compared to marketed lithium salts, examining its ability to achieve far better restorative efficacy while lessening systemic side effects.

High-Resolution Brain Imaging

The medical research study used a crafted head coil established by Tesla Dynamic Coils BV, which approves the capacity for high-resolution, whole-brain lithium imaging, which enables the exact metrology of lithium within certain mind structures.

With minimized systemic exposure, Alzamend’s AL001 solution might stand for a standard change in treating disorders such as Alzheimer’s, by decreasing the threats of kidney and thyroid difficulties frequently associated with conventional lithium programs.

ALZN002 Trial for Alzheimer’s

In April 2023, Alzamend Neuro launched a Phase 1/2A trial for ALZN002 to review its security, tolerability, and effectiveness in 20-30 clients with light to modest Alzheimer’s, comparing numerous rising dosages to a placebo.

Alzamend Neuro AL001 (LiProSal) is an unique, copyrighted dental restorative medication prospect for the therapy of Alzheimer’s condition, bipolar disorder (BD), major depressive problem (MDD), and post-traumatic stress disorder (PTSD). It is made as a much safer and extra reliable lithium-delivery system compared to standard lithium salts.